3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
3
Waldenstrom Macroglobulinemia
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Mantle-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Hairy Cell
1
Burkitt Lymphoma
1
Interventions
Peripheral Blood Stem Cell Transplantation
12
Rituximab
9
Tacrolimus
8
Mycophenolic Acid
8
fludarabine phosphate
7
Cyclophosphamide
7
Whole-Body Irradiation
6
Cyclosporine
5
Radiotherapy
4
Methotrexate
4
Granulocyte Colony-Stimulating Factor
4
Filgrastim
4
Busulfan
4
Antilymphocyte Serum
4
immunotoxin HA22
3
fludarabine
3
Etoposide
3
Dexamethasone
3
Calcium Dobesilate
3
plerixafor
2
merphos
2
Therapeutics
2
Sirolimus
2
Ondansetron
2
Melphalan
2
Ipilimumab
2
Flow Cytometry
2
Diphenhydramine
2
Darbepoetin alfa
2
Cord Blood Stem Cell Transplantation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Leukemia, Hairy Cell
×
brexucabtagene autoleucel
×
Clear all
NCT05537766
2026-03-10
ZUMA-25
Gilead Sciences
Phase 2
Terminated
19 enrolled
28 charts